Time-Varying Cardiovascular Outcomes of Sodium-Glucose Cotransporter Inhibitors in Patients With Type 2 Diabetes: A Post Hoc Analysis of Pivotal Trials Using Restricted Mean Survival Time

Circ Cardiovasc Qual Outcomes. 2023 Mar;16(3):e009491. doi: 10.1161/CIRCOUTCOMES.122.009491. Epub 2023 Mar 1.

Authors

Ioannis Milioglou¹, Issam Motairek¹, Salil Deo², Ravi Ramani¹, Ian J Neeland^{1

3}, Sanjay Rajagopalan^{1

3}, Sadeer G Al-Kindi^{1

3}

Affiliations

¹ Harrington Heart and Vascular Institute, University Hospitals, Cleveland, OH (Ioannis Milioglou, Issam Motairek, R.R., I.J.N., S.R., S.A.-K.).
² Surgical Services, Louis Stokes VA Hospital, Cleveland, OH (S.D.).
³ Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA), University Hospitals, Cleveland, OH (I.J.N., S.R., S.A.-K.).

PMID: 36856041
DOI: 10.1161/CIRCOUTCOMES.122.009491

No abstract available

Keywords: canagliflozin; dapagliflozin; empagliflozin; ertugliflozin; sodium-glucose transporter 2 inhibitor.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2* / diagnosis
Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / adverse effects
Sodium
Survival Rate

Substances

Hypoglycemic Agents
Blood Glucose
Sodium

Grants and funding

P50 MD017351/MD/NIMHD NIH HHS/United States